Lymphoproliferative disease in the rectum 4 years after local mesenchymal stromal cell therapy for refractory perianal Crohn's fistulas: a case report

Barnhoorn, M. C., van Halteren, A. G. S., van Pel, M., Molendijk, I., Struijk, A. C., Jansen, P. M., Verspaget, H. W., Dijkstra, G., Oosten, L. E. M. & van der Meulen-de Jong, A. E., Jun-2019, In : Journal of Crohn's and Colitis. 13, 6, p. 807-811 5 p.

Research output: Contribution to journalArticleAcademicpeer-review

  • Marieke C Barnhoorn
  • Astrid G S van Halteren
  • Melissa van Pel
  • Ilse Molendijk
  • Ada C Struijk
  • Patty M Jansen
  • Hein W Verspaget
  • Gerard Dijkstra
  • Liesbeth E M Oosten
  • Andrea E van der Meulen-de Jong

Mesenchymal stromal cell (MSC) therapy is a new treatment for perianal fistulas in Crohn's disease. Although MSC-therapy shows a favorable safety profile, long-term safety data are limited. We detected an Epstein Barr virus (EBV) associated B cell lymphoproliferative lesion in the rectum of a patient 4 years after local administration of MSCs for his perianal fistulas. To investigate whether MSC-therapy contributed to the development of this lymphoproliferative disease, we analyzed the possibility of EBV transfer via the MSC product and the persistence of MSCs in the lymphoproliferative lesion using short tandem repeat analysis.

Original languageEnglish
Pages (from-to)807-811
Number of pages5
JournalJournal of Crohn's and Colitis
Issue number6
Publication statusPublished - Jun-2019

Download statistics

No data available

ID: 77028661